Jazz Pharmaceuticals Plc - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Jazz Pharmaceuticals Plc on February 21, 2024. The filing primarily addresses Item 5.02 regarding the appointment of a new Chief Financial Officer and Item 7.01 regarding Regulation FD disclosure of a press release.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on executive compensation and personnel changes rather than financial performance results.
Material Changes
The material change reported is the appointment of Philip Johnson as Executive Vice President and Chief Financial Officer, effective March 1, 2024. Mr. Johnson will succeed Patricia Carr, who has served as the principal financial officer on an interim basis.
Management Commentary and Compensation Details
Mr. Johnson's compensation package includes the following terms:
- Base Salary: $700,000 annually.
- Target Bonus: 65% of annual base salary.
- Signing Bonus: $150,000.
- Equity Grant: A new hire grant of Jazz Ordinary Shares with an approximate grant date value of $4,000,000, consisting of an equal mix of restricted stock units (vesting in four equal annual installments) and performance stock units (vesting based on conditions established in Q1 2024).
Mr. Johnson previously served as Group Vice President of Finance and Treasurer at Eli Lilly and Company from January 2018 to March 2024.
Investor Verification Checklist
- Verify the exact vesting conditions for the performance stock units to be established in Q1 2024.
- Review the full Offer Letter to be filed as an exhibit to the Form 10-Q for the quarter ended March 31, 2024.
- Confirm the transition timeline for Patricia Carr's departure from the interim CFO role.
- Check the 2011 Equity Incentive Plan and Severance Plan documents referenced in the filing for specific terms applicable to Mr. Johnson.